Cargando…

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

Imatinib has revolutionised the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal tumours (GIST). Using a nonlinear mixed effects population model, individual estimates of pharmacokinetic parameters were derived and used to estimate imatinib exposure (area under the curve, AU...

Descripción completa

Detalles Bibliográficos
Autores principales:	Widmer, N, Decosterd, L A, Leyvraz, S, Duchosal, M A, Rosselet, A, Debiec-Rychter, M, Csajka, C, Biollaz, J, Buclin, T
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391118/ https://www.ncbi.nlm.nih.gov/pubmed/18475296 http://dx.doi.org/10.1038/sj.bjc.6604355

Ejemplares similares

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib
por: Buclin, Thierry, et al.
Publicado: (2020)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
por: Wang, J, et al.
Publicado: (2012)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome
por: Akçakaya, P, et al.
Publicado: (2014)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study
por: Klawitter, J, et al.
Publicado: (2009)

Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation
por: Vlahovic, G, et al.
Publicado: (2006)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure
por: Goutelle, Sylvain, et al.
Publicado: (2023)

Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy
por: Keidar, M, et al.
Publicado: (2011)

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
por: Naing, A, et al.
Publicado: (2012)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer
por: Ramcharan, K S, et al.
Publicado: (2014)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

Interleukin-10-regulated tumour tolerance in non-small cell lung cancer
por: Vahl, Julius Malte, et al.
Publicado: (2017)

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide
por: Orlandi, P, et al.
Publicado: (2013)

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer
por: Smith, G, et al.
Publicado: (2012)

Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients
por: Lam, Siu W, et al.
Publicado: (2016)

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder
por: Hilmy, M, et al.
Publicado: (2006)

Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma
por: Campbell, L, et al.
Publicado: (2008)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

The prognostic value of dynamic contrast-enhanced MRI contrast agent transfer constant K(trans) in cervical cancer is explained by plasma flow rather than vessel permeability
por: Dickie, Ben R, et al.
Publicado: (2017)

NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel
por: Negishi, T, et al.
Publicado: (2006)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Relationship between subcellular localisation of Foscan® and caspase activation in photosensitised MCF-7 cells
por: Marchal, S, et al.
Publicado: (2007)

Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR(+), HER2(−) advanced breast cancer: results from BOLERO-2
por: Moynahan, Mary Ellen, et al.
Publicado: (2017)

A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
por: Koti, M, et al.
Publicado: (2015)

Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
por: Olsson, A, et al.
Publicado: (2007)

Use of interfering RNA to investigate the role of endogenous gastrin in the survival of gastrointestinal cancer cells
por: Grabowska, A M, et al.
Publicado: (2007)

Activated 4E-BP1 represses tumourigenesis and IGF-I-mediated activation of the eIF4F complex in mesothelioma
por: Jacobson, B A, et al.
Publicado: (2009)

Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
por: Cellai, C, et al.
Publicado: (2006)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay
por: Zlotnik, Y, et al.
Publicado: (2005)

Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma
por: Fiaschetti, G, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_01a6um4g8n8e077tibusthj6e7